Introduction Vaccination represents a cornerstone in mastering the COVID-19 pandemic.
Data on immunogenicity and safety of messenger RNA (mRNA) vaccines in patients with …

Background Despite the high efficacy of the BNT162b2 messenger RNA vaccine against
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), rare breakthrough …

The first emergency-use authorizations for COVID-19 vaccines were granted by the Food
and Drug Administration in December 2020, and clinical trials for the approval of more …

Objective To evaluate the effect on immunogenicity and safety of 2-week methotrexate
(MTX) discontinuation after each dose of the Sinovac-CoronaVac vaccine versus MTX …

Objectives Adolescents with juvenile-onset autoimmune inflammatory rheumatic diseases
(AIIRDs) could be at risk for disease flare secondary to severe acute respiratory syndrome …

ABSTRACT SARS-CoV-2 anti-spike antibody concentrations and angiotensin converting
enzyme-2 (ACE-2) inhibition have been used as surrogates to live viral neutralizing antibody …

Severe acute respiratory disease coronavirus 2 is currently causing the coronavirus disease
2019 (COVID-19) pandemic, placing extreme strain on the global health system. Vaccination …

Objectives To evaluate long-term kinetics of the BNT162b2 mRNA vaccine-induced immune
response in adult patients with autoimmune inflammatory rheumatic diseases (AIIRD) and …

Background: Studies reporting the long-term humoral response after receiving the
BNT162b2 COVID-19 vaccine are important to drive future vaccination strategies. Yet …

Pan-immunoglobulin assays can simultaneously detect IgG, IgM and IgA directed against
the receptor binding domain (RBD) of the S1 subunit of the spike protein (S) of severe acute …